

Company Number: 245071

BROGANS PHARMACY LIMITED
Abridged Unaudited Financial Statements
for the financial year ended 30 April 2025

BROGANS PHARMACY LIMITED CONTENTS

	Page
Directors' Responsibilities Statement	3
Accountants' Report	4
Balance Sheet	5 - 6
Notes to the Financial Statements	7 - 12

BROGANS PHARMACY LIMITED

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 April 2025

The directors made the following statement in respect of the unaudited financial statements:

"General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available to Michael Kelly & Co, (Certified Public Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 30 April 2025."

Signed on behalf of the board

Amber Staunton
Director

Anne Staunton
Director

Patrick Staunton
Director

22 January 2026

22 January 2026

BROGANS PHARMACY LIMITED
CERTIFIED PUBLIC ACCOUNTANTS REPORT
to the Board of Directors on the Compilation of the unaudited Abridged financial
statements of BROGANS PHARMACY LIMITED
for the financial year ended 30 April 2025

In accordance with our engagement letter and in order to assist you to fulfil your duties under the Companies Act 2014, we have compiled for your approval the abridged financial statements of the company for the financial year ended 30 April 2025 as set out on pages 5 to 12 which comprise the Balance Sheet and the related notes from the company's accounting records and information and explanations you have given to us.

This report is made solely to the Board of Directors of BROGANS PHARMACY LIMITED, as a body, in accordance with the terms of our engagement. Our work has been undertaken so that we might compile the financial statements that we have been engaged to compile, report to the company's Board of Directors that we have done so, and state those matters that we have agreed to state to them in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and its Board of Directors, as a body, for our work or for this report.

We compiled the financial statements in accordance with the guidance contained in Compilation Engagements Technical Statement and the International Standard on Related Services 4410 (Revised), Compilation Engagements from the accounting records and information and explanations supplied to us by the directors. We have applied our expertise in accounting and financial reporting to assist you in the preparation and presentation of these financial statements in accordance with Financial Reporting Standard 102 ("FRS 102"), the Financial Reporting Standard applicable in the Republic of Ireland and Irish statute comprising the Companies Act 2014. We have complied with relevant ethical requirements, including principles of integrity, objectivity, professional competence and due care.

You have acknowledged on the Balance Sheet for the year ended 30 April 2025 your duty to ensure that BROGANS PHARMACY LIMITED has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of BROGANS PHARMACY LIMITED. You consider that BROGANS PHARMACY LIMITED is exempt from the statutory audit requirement for the financial year.

We have not been instructed to carry out an audit or a review of the abridged financial statements of BROGANS PHARMACY LIMITED. For this reason, we have not verified the adequacy, accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory abridged financial statements.

MICHAEL KELLY & CO

Certified Public Accountants and Registered Auditor
Spencer Street
Castlebar
Mayo
Ireland

22 January 2026

BROGANS PHARMACY LIMITED

BALANCE SHEET

as at 30 April 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	7	<u>456,452</u>	<u>457,024</u>
Current Assets			
Stocks	8	182,191	193,720
Debtors	9	3,619,271	4,393,647
Cash and cash equivalents		<u>8,050</u>	<u>37,934</u>
		<u>3,809,512</u>	<u>4,625,301</u>
Creditors: amounts falling due within one year	10	<u>(295,863)</u>	<u>(600,514)</u>
Net Current Assets		<u>3,513,649</u>	<u>4,024,787</u>
Total Assets less Current Liabilities		3,970,101	4,481,811
Creditors:			
amounts falling due after more than one year	11	<u>(25,911)</u>	<u>(211,090)</u>
Net Assets		<u><u>3,944,190</u></u>	<u><u>4,270,721</u></u>
Capital and Reserves			
Called up share capital presented as equity		1,270	1,270
Retained earnings		<u>3,942,920</u>	<u>4,269,451</u>
Equity attributable to owners of the company		<u><u>3,944,190</u></u>	<u><u>4,270,721</u></u>

BROGANS PHARMACY LIMITED

BALANCE SHEET

as at 30 April 2025

We as Directors of BROGANS PHARMACY LIMITED, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 22 January 2026 and signed on its behalf by:

Amber Staunton
Director

Anne Staunton
Director

Patrick Staunton
Director

BROGANS PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

1. General Information

BROGANS PHARMACY LIMITED is a company limited by shares incorporated in Ireland. The registered office of the company is Main Street, Loughrea, Galway, Ireland which is also the principal place of business of the company. The company's principal activity is that of retailing pharmaceutical products. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

Statement of compliance

The financial statements of the company for the year ended 30 April 2025 have been prepared on the going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102).

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014.

Cash flow statement

The company has availed of the exemption in FRS 102 from the requirement to prepare a Cash Flow Statement because it is classified as a small company.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Functional Currency

The functional currency of the financial statements is the euro.

Significant Accounting Judgements

Management is required to make judgements in the process of applying the company's accounting policies. The key judgement made in these financial statements is that the value placed on the closing stock as disclosed in note 7 to the financial statements is realisable.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	-	4% Straight line
Fixtures, fittings and equipment	-	15% Straight line
Motor vehicles	-	25% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

BROGANS PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company provides a range of benefits, including annual bonus arrangements, paid holiday arrangements and defined contribution pension schemes.

Short term benefits

Short term benefits, including holiday pay and other similar non-monetary benefits, are recognised as an expense in the period in which the service is rendered.

Retirement Benefits

Retirement benefits are met by payments to a defined contribution pension fund. Contributions are charged to the profit and loss in the year in which they fall due.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating (loss)/profit	2025	2024
	€	€
Operating (loss)/profit is stated after charging:		
Depreciation of tangible assets	44,978	39,509
Profit on disposal of intangible fixed assets	(647)	(250)
	<u> </u>	<u> </u>

BROGANS PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

4. Interest payable and similar expenses	2025	2024
	€	€
Interest	<u>8,867</u>	<u>11,961</u>

5. Employees

The average monthly number of employees, including directors, during the financial year was 11, (2024 - 13).

	2025	2024
	Number	Number
Pharmacist's	3	3
Sales Staff	10	10
	<u>13</u>	<u>13</u>

6. Tax on (loss)/profit

	2025	2024
	€	€

(a) Analysis of charge in the financial year

Current tax:

Corporation tax at 12.50% (2024 - 12.50%) (Note 6 (b))	-	14,149
	<u>-</u>	<u>14,149</u>

(b) Factors affecting tax charge for the financial year

The tax assessed for the financial year differs from the standard rate of corporation tax in the Republic of Ireland 12.50% (2024 - 12.50%). The differences are explained below:

	2025	2024
	€	€
(Loss)/profit taxable at 12.50%	<u>(326,531)</u>	<u>107,214</u>
(Loss)/profit before tax multiplied by the standard rate of corporation tax in the Republic of Ireland at 12.50% (2024 - 12.50%)	(40,816)	13,402
Effects of:		
Depreciation in excess of capital allowances for period	1,061	747
Utilisation of tax losses	39,755	-
Total tax charge for the financial year (Note 6 (a))	<u>-</u>	<u>14,149</u>

No charge to tax arises due to tax losses incurred.

BROGANS PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

7. Tangible assets

	Land and buildings freehold €	Fixtures, fittings and equipment €	Motor vehicles €	Total €
Cost				
At 1 May 2024	311,258	504,858	-	816,116
Additions	-	1,671	47,267	48,938
Disposals	-	(5,179)	-	(5,179)
At 30 April 2025	311,258	501,350	47,267	859,875
Depreciation				
At 1 May 2024	24,900	334,192	-	359,092
Charge for the financial year	6,225	32,845	5,908	44,978
On disposals	-	(647)	-	(647)
At 30 April 2025	31,125	366,390	5,908	403,423
Net book value				
At 30 April 2025	280,133	134,960	41,359	456,452
At 30 April 2024	286,358	170,666	-	457,024

8. Stocks

	2025 €	2024 €
Finished goods and goods for resale	182,191	193,720

The replacement cost of stock did not differ significantly from the figures shown.

9. Debtors

	2025 €	2024 €
Trade debtors	106,193	108,226
Amounts owed by group undertakings	3,403,919	4,171,706
Other debtors	-	5,000
Taxation	103,210	106,915
Prepayments	5,949	1,800
	3,619,271	4,393,647

10. Creditors

Amounts falling due within one year	2025 €	2024 €
Amounts owed to credit institutions	916	90,501
Net obligations under finance leases and hire purchase contracts	8,403	-
Trade creditors	151,608	251,139
Amounts owed to related parties (Note 15)	110,000	90,000
Taxation	13,100	26,037
Directors' current accounts (Note 14)	3,766	109,820
Other creditors	-	5,569
Accruals	8,070	27,448
	295,863	600,514

BROGANS PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

11. Creditors	2025	2024
Amounts falling due after more than one year	€	€
Bank loan	-	211,090
Finance leases and hire purchase contracts	25,911	-
	<u>25,911</u>	<u>211,090</u>
Loans		
Repayable in one year or less, or on demand	916	90,501
Repayable between one and two years	-	59,882
Repayable between two and five years	-	133,233
Repayable in five years or more	-	17,975
	<u>916</u>	<u>301,591</u>
Net obligations under finance leases and hire purchase contracts		
Repayable within one year	8,403	-
Repayable between one and five years	25,911	-
	<u>34,314</u>	<u>-</u>
12. Income Statement		
	2025	2024
	€	€
At 1 May 2024	4,269,451	4,176,386
(Loss)/profit for the financial year	(326,531)	93,065
	<u>3,942,920</u>	<u>4,269,451</u>
13. Capital commitments		
The company had no material capital commitments at the financial year-ended 30 April 2025.		
14. Directors' remuneration and transactions	2025	2024
	€	€
Remuneration	115,908	80,029
Pension contributions	231,145	15,000
Compensation for loss of office from company	200,000	-
	<u>547,053</u>	<u>95,029</u>
The following amounts are repayable to the directors:		
	2025	2024
	€	€
Jack Staunton	3,766	3,810
Anne Staunton	-	106,010
	<u>3,766</u>	<u>109,820</u>
15. Related party transactions		
The company has availed of the exemption under FRS 102 in relation to the disclosure of transactions with group undertakings.		

BROGANS PHARMACY LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

16. Parent company

The company regards Gencare Healthcare Services Limited as its parent company.

is regarded as both the controlling party and the ultimate controlling party.
Gencare Healthcare Services Limited is registered in Ireland.

17. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

18. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 22 January 2026.